Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/41463
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorZuluaga Idárraga, Lina Marcela-
dc.contributor.authorAbreha, Tesfay-
dc.contributor.authorAwab, Ghulam Rahim-
dc.contributor.authorBaird, J. Kevin-
dc.contributor.authorBrasil, Larissa W.-
dc.contributor.authorChu, Cindy S.-
dc.contributor.authorCommons, Robert J.-
dc.contributor.authorCui, Liwang-
dc.contributor.authorDaher, André-
dc.contributor.authorDini, Saber-
dc.contributor.authorGonzalez Ceron, Lilia-
dc.contributor.authorGomes, Margarete do Socorro M.-
dc.contributor.authorGuerin, Philippe J.-
dc.contributor.authorHwang, Jimee-
dc.contributor.authorKarunajeewa, Harin-
dc.contributor.authorLacerda, Marcus V. G.-
dc.contributor.authorLadeia Andrade, Simone-
dc.contributor.authorLeslie, Toby-
dc.contributor.authorLey, Benedikt-
dc.contributor.authorLidia, Kartini-
dc.contributor.authorLlanos Cuentas, Alejandro-
dc.contributor.authorLongley, Rhea J.-
dc.contributor.authorMehdipour, Parinaz-
dc.contributor.authorMonteiro, Wuelton Marcelo-
dc.contributor.authorPereira, Dhelio B-
dc.contributor.authorPrice, Ric N-
dc.contributor.authorRajasekhar, Megha-
dc.contributor.authorRijal, Komal Raj-
dc.contributor.authorSaravu, Kavitha-
dc.contributor.authorSimpson, Julie A.-
dc.contributor.authorSutanto, Inge-
dc.contributor.authorTaylor, Walter R. J.-
dc.contributor.authorThanh, Pham Vinh-
dc.contributor.authorThriemer, Kamala-
dc.contributor.authorVieira, José Luiz F.-
dc.contributor.authorWhite, Nicholas J.-
dc.contributor.authorZaloumis, Sophie-
dc.contributor.authorAdam, Ishag-
dc.date.accessioned2024-08-26T17:04:04Z-
dc.date.available2024-08-26T17:04:04Z-
dc.date.issued2023-
dc.identifier.citationMehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, Awab GR, Baird JK, Brasil LW, Chu CS, Cui L, Daher A, do Socorro M Gomes M, Gonzalez-Ceron L, Hwang J, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Leslie T, Ley B, Lidia K, Llanos-Cuentas A, Longley RJ, Monteiro WM, Pereira DB, Rijal KR, Saravu K, Sutanto I, Taylor WRJ, Thanh PV, Thriemer K, Vieira JLF, White NJ, Zuluaga-Idarraga LM, Guerin PJ, Price RN, Simpson JA, Commons RJ; WWARN Vivax Adherence Study Group. Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. Malar J. 2023 Oct 10;22(1):306. doi: 10.1186/s12936-023-04725-w.spa
dc.identifier.urihttps://hdl.handle.net/10495/41463-
dc.description.abstractABSTRACT: Background: Imperfect adherence is a major barrier to effective primaquine radical cure of Plasmodium vivax. This study investigated the effect of reduced adherence on the risk of P. vivax recurrence. Methods: Efficacy studies of patients with uncomplicated P. vivax malaria, including a treatment arm with daily primaquine, published between January 1999 and March 2020 were identified. Individual patient data from eligible studies were pooled using standardized methodology. Adherence to primaquine was inferred from i) the percentage of supervised doses and ii) the total mg/kg dose received compared to the target total mg/kg dose per protocol. The effect of adherence to primaquine on the incidence of P. vivax recurrence between days 7 and 90 was investigated by Cox regression analysis. Results: Of 82 eligible studies, 32 were available including 6917 patients from 18 countries. For adherence assessed by percentage of supervised primaquine, 2790 patients (40.3%) had poor adherence (≤ 50%) and 4127 (59.7%) had complete adherence. The risk of recurrence by day 90 was 14.0% [95% confidence interval: 12.1-16.1] in patients with poor adherence compared to 5.8% [5.0-6.7] following full adherence; p = 0.014. After controlling for age, sex, baseline parasitaemia, and total primaquine dose per protocol, the rate of the first recurrence was higher following poor adherence compared to patients with full adherence (adjusted hazard ratio (AHR) = 2.3 [1.8-2.9]). When adherence was quantified by total mg/kg dose received among 3706 patients, 347 (9.4%) had poor adherence, 88 (2.4%) had moderate adherence, and 3271 (88.2%) had complete adherence to treatment. The risks of recurrence by day 90 were 8.2% [4.3-15.2] in patients with poor adherence and 4.9% [4.1-5.8] in patients with full adherence; p < 0.001. Conclusion: Reduced adherence, including less supervision, increases the risk of vivax recurrence. Keywords: Adherence; Malaria; Plasmodium vivax; Primaquine; Rate of recurrence; Supervision.spa
dc.format.extent14 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherBMC (BioMed Central)spa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/co/*
dc.titleEffect of Adherence to Primaquine on the Risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network Systematic Review and Individual Patient data Meta-analysisspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGrupo Malariaspa
dc.identifier.doi10.1186/s12936-023-04725-w-
dc.contributor.corporatenameWWARN Vivax Adherence Study Groupspa
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1475-2875-
oaire.citationtitleMalaria Journalspa
oaire.citationstartpage1spa
oaire.citationendpage14spa
oaire.citationvolume22spa
oaire.citationissue1spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by/4.0/spa
oaire.fundernameWellcome Trustspa
oaire.fundernameNational Health and Medical Research Councilspa
dc.publisher.placeLondres, Inglaterraspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsAntimaláricos-
dc.subject.decsAntimalarials-
dc.subject.decsAntagonistas del Ácido Fólico-
dc.subject.decsFolic Acid Antagonists-
dc.subject.decsMalaria Vivax-
dc.subject.decsMalaria, Vivax-
dc.subject.decsPlasmodium vivax-
dc.subject.decsPrimaquina-
dc.subject.decsPrimaquine-
dc.description.researchgroupidCOL0007524spa
oaire.awardnumberNHMRC 1194702, 1196068, 2008501spa
oaire.awardnumbergrant 089179 to CSC, FN and NJWspa
oaire.awardnumber093956/Z/10/Cspa
oaire.awardnumber1134989spa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000962-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D005493-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D016780-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D010966-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D011319-
dc.relation.ispartofjournalabbrevMalar. J.spa
oaire.funderidentifier.rorRoR:029chgv08-
oaire.funderidentifier.rorRoR:011kf5r70-
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
ZuluagaLina_2023_Effect_Adherence_Vivax.pdfArtículo de investigación1.13 MBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons